NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03794440,A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.,https://clinicaltrials.gov/study/NCT03794440,,UNKNOWN,"The purpose of the study is to assess the safety, tolerability and effectiveness of Sintilimab in combination with IBI305 in patients with HCC as the first-line treatment compared with Sorafenib. This study is a randomised, Open-label，Multi-center Study. The primary endpoint is overall survival.",NO,Hepatocellular Carcinoma,DRUG: Sintilimab|DRUG: IBI305|DRUG: Sorafenib,"Overall survival (OS), up to 24 months after randomization|Progression-free survival (PFS), Progression-free survival (PFS) in two arms based on RECIST V1.1 by Independent Radiological Review Committee, IRRC., up to 24 months after randomization","PFS, PFS in two arms based on RECIST V1.1 by investigator., up to 24 months after randomization|Objective response rate (ORR), Objective response rate (ORR) in two arms based on RECIST V1.1 by IRRC and investigator ., up to 24 months after randomization|Disease control rate (DCR), DCR in two arms based on RECIST V1.1 by IRRC and investigator., up to 24 months after randomization|Duration of response (DOR), DOR in two arms based on RECIST V1.1 by IRRC and investigator., up to 24 months after randomization|Time to progression (TTP), TTP in two arms based on RECIST V1.1 by IRRC and investigator., One assessment was performed every 6 weeks (±7 days) from the time of randomization, and once every 12 weeks (±7 days) after 48 weeks.|Time to response (TTR), TTR in two arms based on RECIST V1.1 by IRRC and investigator., up to 24 months after randomization|PFS, PFS in two arms based on mRECIST by IRRC., up to 24 months after randomization|Objective response rate (ORR), Objective response rate (ORR) in two arms based on mRECIST by IRRC., up to 24 months after randomization|Time to progression (TTP), TTP in two arms based on mRECIST by IRRC., up to 24 months after randomization|Duration of response (DOR), DOR in two arms based on mRECIST by IRRC., up to 24 months after randomization|Disease control rate (DCR), DCR in two arms based on mRECIST by IRRC., up to 24 months after randomization|Time to response (TTR), TTR in two arms based on mRECIST by IRRC., up to 24 months after randomization|Anti-drug antibody (ADA), Immunogenicity measured by anti-drug antibody (ADA) for Sintilimab and IBI305., up to 24 months after randomization|EORTC QLQ-C30, up to 24 months after randomization|EORTC QLQ-HCC18, up to 24 months after randomization",,Innovent Biologics (Suzhou) Co. Ltd.,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,595,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CIBI338B301,2019-02-11,2022-12,2022-12,2019-01-07,,2021-01-22,"Hospital of Fudan University, Shanghai, Shanghai, 200032, China",
